Lutetium Lu-177 Dotatate Flare Reaction

PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Salner, Andrew L., Blankenship, Bette, Dunnack, Hayley, Niemann, Christopher, Bertsch, Helaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811111/
https://www.ncbi.nlm.nih.gov/pubmed/33490736
http://dx.doi.org/10.1016/j.adro.2020.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811111/
https://www.ncbi.nlm.nih.gov/pubmed/33490736
http://dx.doi.org/10.1016/j.adro.2020.11.008

Ejemplares similares